We further demonstrate that TRPV1 is expressed in liver tissue and its activation by CAP enhances PPARα, PGC-1α, and UCP2 expression, promoting fatty acid oxidation, reducing hepatic lipid burden, and inhibiting MASLD progression. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.